Takeda Pharmaceutical Company Limited (TAK) — Business segments and KPIs
Revenue by business segment and geography for Takeda Pharmaceutical Company Limited, with year-over-year trends.
FY 2024
| Segment | Revenue | % of total |
|---|---|---|
| Revenue by product | ||
| Gastroenterology | 1.36T | 29.6% |
| PDT Immunology | 1.03T | 22.5% |
| Rare Diseases | 752.82B | 16.4% |
| Neuroscience | 565.82B | 12.3% |
| Oncology | 560.43B | 12.2% |
| Other Product | 257.39B | 5.6% |
| Vaccines | 55.41B | 1.2% |
| Revenue by region | ||
| UNITED STATES | 2.38T | 52.8% |
| Europe And Canada | 1.06T | 23.4% |
| JAPAN | 418.46B | 9.3% |
| Latin America | 235.85B | 5.2% |
| CHINA | 191.74B | 4.3% |
| Other Countries Not Separately Reported | 128.85B | 2.9% |
| Asia, Excluding Japan And China | 99.39B | 2.2% |